Special Issue

Cancer Chemotherapy: Combination with Inhibitors

Message from the Guest Editors

Several different molecular pathways have been implicated in the development of resistance, including those regulating stress responses, such as autophagy, unfolded protein response (UPR), DNA damage response (DDR), antioxidant response, and heat shock response (HSR). Unfortunately, following the inhibition of one of the oncogenic pathways, cancer cells may hyperactivate others to keep surviving. Therefore, to combat drug resistance, combination therapies targeting several molecular pathways and their-induced protective processes seem to be more promising than a single targeted therapy especially if they result also in anti-cancer immune activation. This Special Issue aims to collect research articles, Reviews and Communications focused on (but not limited to) *experimental* studies in the research area of chemoresistance and combination therapies with inhibitors to overcome or prevent potential drug resistance.

Guest Editors

Dr. Mara Cirone

Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy

Dr. Gabriella D'Orazi

1. Department of Neuroscience and Imaging, University G. D'Annunzio, 66013 Chieti, Italy
2. Department of Research, Unit of Cellular Network and Therapeutic Innovation, Regina Elena National Cancer Institute, 00144 Rome, Italy

Deadline for manuscript submissions

closed (31 May 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/124407

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)